Skip to main content
OpenTrials
Completed

NCT Number: NCT07605260

Effect of Intravenous Mannitol on Anterior Chamber Depth and Intraocular Pressure.

Local data regarding the effectiveness and safety of mannitol has been scarce. Therefore, the current study was planned, aiming to compare the change in mean anterior chamber depth and intraocular pressure (IOP) and to determine the frequencies of perioperative complications during cataract surgery in groups receiving mannitol versus placebo.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cataract Eye Diseases Lens Diseases

Age range

30 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Pakistan Air Force (PAF) hospital

Islamabad, Punjab Province, 44000, Pakistan

About this study

The literature shows that the effectiveness of mannitol in decreasing intraocular pressure (IOP) varies widely. Although it rapidly lowers IOP in the majority of people, clinical results and the extent of the reduction differ depending on a number of factors. Mannitol can be detrimental for patients with pulmonary edema or severe heart failure (congestive heart failure) because it quickly draws fluid into the bloodstream, increasing intravascular volume. In addition to contributing to the local literature, the results of this study will aid in determining the true efficacy and safety of mannitol.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients of any gender
  • Aged 30-80 years
  • Undergoing cataract surgery

Exclusion criteria

  • Patients with glaucoma, uveitis, or corneal pathology
  • With trauma
  • Previously had surgery
  • With exfoliation syndrome
  • Had iridotomies
  • Had use of sympathetic α1 antagonist

Treatment and study plan

Mannitol

Drug

After employing standard protocol for dilatation, intravenous mannitol at 1g/kg over a period of 30 minutes was administered to the patients.

Placebo

Drug

After employing standard protocol for dilatation, patients were given a placebo.

Primary outcomes

  1. Change in the intraocular pressure

    Time frame: 45 minutes

    The change in the intraocular pressure, measured in mmHg, was noted at post-intervention and compared to the baseline.

  2. Change in the anterior chamber depth

    Time frame: 45 minutes

    The change in the anterior chamber depth, measured in mm, was noted at post-intervention and compared to the baseline.

Sponsors and collaborators

Lead sponsor

Muhammad Aamir Latif

Other

Registry information

Official study title

Effect of Intravenous Mannitol on Anterior Chamber Depth and Intraocular Pressure in Patients Before Cataract Surgery.

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
May 22, 2026
Registry last updated
Jul 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.